Skip to main content
Top
Published in: Heart and Vessels 3/2015

01-05-2015 | Original Article

Impact of sleep-disordered breathing on myocardial damage and metabolism in patients with chronic heart failure

Authors: Makiko Miyata, Akiomi Yoshihisa, Hiroyuki Yamauchi, Takashi Owada, Takamasa Sato, Satoshi Suzuki, Koichi Sugimoto, Takayoshi Yamaki, Hiroyuki Kunii, Kazuhiko Nakazato, Hitoshi Suzuki, Shu-ichi Saitoh, Yasuchika Takeishi

Published in: Heart and Vessels | Issue 3/2015

Login to get access

Abstract

Sleep-disordered breathing (SDB) has a critical association with mortality and morbidity of patients with chronic heart failure (CHF). Troponin T is a marker of ongoing myocardial damage and predicts adverse clinical outcomes in patients with CHF. Carnitine plays an important role in the utilization of fatty acids in the myocardium. It has been reported that myocardial carnitine levels decrease in the failing heart. We hypothesized that plasma troponin T and carnitine are increased due to the leakage from damaged cardiomyocytes or the alteration of myocardial metabolism in CHF patients with SDB. We examined the relation of plasma troponin T and carnitine levels with severity of SDB in CHF. We used portable sleep monitor and measured the apnea–hypopnea index (AHI), plasma levels of high-sensitive troponin T and carnitine in 131 CHF patients. These patients were divided into three groups based on AHI: group A (None–mild SDB AHI < 15/h, n = 45), group B (Moderate SDB 15 ≤ AHI < 30/h, n = 32) and group C (Severe SDB AHI ≥ 30/h, n = 54). Levels of high-sensitive troponin T and plasm total carnitine were significantly higher in group C than in groups A and B [high-sensitive troponin T; group A 0.009 (0.005–0.016), group B 0.012 (0.006–0.021), group C 0.021 (0.011–0.039) ng/ml, total carnitine; group A 61.0 ± 15.1, group B 65.0 ± 13.5, group C 73.3 ± 17.5 μmol/l, P < 0.01 vs. group A and P < 0.05 vs. group B, respectively]. Furthermore, in the multiple regression analysis, the independent factors to determine plasma levels of log (high-sensitive troponin T) were high-sensitive C-reactive protein and AHI, and the independent factors to determine plasma levels of carnitine were glomerular filtration rate and AHI. The present study suggests that SDB is associated with latent myocardial damage and alteration of myocardial carnitine metabolism in patients with CHF, presented by higher circulating troponin T and carnitine levels.
Literature
1.
go back to reference Javaheri S, Shukla R, Zeigler H, Wexler L (2007) Central sleep apnea, right ventricular dysfunction, and low diastolic blood pressure are predictors of mortality in systolic heart failure. J Am Coll Cardiol 49:2028–2034CrossRefPubMed Javaheri S, Shukla R, Zeigler H, Wexler L (2007) Central sleep apnea, right ventricular dysfunction, and low diastolic blood pressure are predictors of mortality in systolic heart failure. J Am Coll Cardiol 49:2028–2034CrossRefPubMed
2.
go back to reference Wang H, Parker JD, Newton GE, Floras JS, Mak S, Chiu KL, Ruttanaumpawan P, Tomlinson G, Bradley TD (2007) Influence of obstructive sleep apnea on mortality in patients with heart failure. J Am Coll Cardiol 49:1625–1631CrossRefPubMed Wang H, Parker JD, Newton GE, Floras JS, Mak S, Chiu KL, Ruttanaumpawan P, Tomlinson G, Bradley TD (2007) Influence of obstructive sleep apnea on mortality in patients with heart failure. J Am Coll Cardiol 49:1625–1631CrossRefPubMed
3.
go back to reference Bitter T, Westerheide N, Prinz C, Hossain MS, Vogt J, Langer C, Horstkotte D, Oldenburg O (2011) Cheyne-Stokes respiration and obstructive sleep apnoea are independent risk factors for malignant ventricular arrhythmias requiring appropriate cardioverter-defibrillator therapies in patients with congestive heart failure. Eur Heart J 32:61–74CrossRefPubMed Bitter T, Westerheide N, Prinz C, Hossain MS, Vogt J, Langer C, Horstkotte D, Oldenburg O (2011) Cheyne-Stokes respiration and obstructive sleep apnoea are independent risk factors for malignant ventricular arrhythmias requiring appropriate cardioverter-defibrillator therapies in patients with congestive heart failure. Eur Heart J 32:61–74CrossRefPubMed
4.
go back to reference Latini R, Masson S, Anand IS, Missov E, Carlson M, Vago T, Angelici L, Barlera S, Parrinello G, Maggioni AP, Tognoni G, Cohn JN (2007) Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Circulation 116:1242–1249CrossRefPubMed Latini R, Masson S, Anand IS, Missov E, Carlson M, Vago T, Angelici L, Barlera S, Parrinello G, Maggioni AP, Tognoni G, Cohn JN (2007) Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Circulation 116:1242–1249CrossRefPubMed
5.
go back to reference Ather S, Hira RS, Shenoy M, Fatemi O, Deswal A, Aguilar D, Ramasubbu K, Bolos M, Chan W, Bozkurt B (2013) Recurrent low-level Troponin I elevation is a worse prognostic indicator than occasional injury pattern in patients hospitalized with heart failure. Int J Cardiol 166:394–398CrossRefPubMed Ather S, Hira RS, Shenoy M, Fatemi O, Deswal A, Aguilar D, Ramasubbu K, Bolos M, Chan W, Bozkurt B (2013) Recurrent low-level Troponin I elevation is a worse prognostic indicator than occasional injury pattern in patients hospitalized with heart failure. Int J Cardiol 166:394–398CrossRefPubMed
6.
go back to reference Masson S, Anand I, Favero C, Barlera S, Vago T, Bertocchi F, Maggioni AP, Tavazzi L, Tognoni G, Cohn JN, Latini R (2012) Serial measurement of cardiac troponin T using a highly sensitive assay in patients with chronic heart failure: data from 2 large randomized clinical trials. Circulation 125:280–288CrossRefPubMed Masson S, Anand I, Favero C, Barlera S, Vago T, Bertocchi F, Maggioni AP, Tavazzi L, Tognoni G, Cohn JN, Latini R (2012) Serial measurement of cardiac troponin T using a highly sensitive assay in patients with chronic heart failure: data from 2 large randomized clinical trials. Circulation 125:280–288CrossRefPubMed
7.
go back to reference Nakamura Y, Yoshihisa A, Takiguchi M, Shimizu T, Yamauchi H, Iwaya S, Owada T, Miyata M, Abe S, Sato T, Suzuki S, Oikawa M, Kobayashi A, Yamaki T, Sugimoto K, Kunii H, Nakazato K, Suzuki H, Saitoh S, Takeishi Y (2013) High-sensitivity cardiac troponin T predicts non-cardiac mortality in heart failure. Circ J Nakamura Y, Yoshihisa A, Takiguchi M, Shimizu T, Yamauchi H, Iwaya S, Owada T, Miyata M, Abe S, Sato T, Suzuki S, Oikawa M, Kobayashi A, Yamaki T, Sugimoto K, Kunii H, Nakazato K, Suzuki H, Saitoh S, Takeishi Y (2013) High-sensitivity cardiac troponin T predicts non-cardiac mortality in heart failure. Circ J
8.
go back to reference Tripp ME, Katcher ML, Peters HA, Gilbert EF, Arya S, Hodach RJ, Shug AL (1981) Systemic carnitine deficiency presenting as familial endocardial fibroelastosis: a treatable cardiomyopathy. N Engl J Med 305:385–390CrossRefPubMed Tripp ME, Katcher ML, Peters HA, Gilbert EF, Arya S, Hodach RJ, Shug AL (1981) Systemic carnitine deficiency presenting as familial endocardial fibroelastosis: a treatable cardiomyopathy. N Engl J Med 305:385–390CrossRefPubMed
9.
go back to reference Waber LJ, Valle D, Neill C, DiMauro S, Shug A (1982) Carnitine deficiency presenting as familial cardiomyopathy: a treatable defect in carnitine transport. J Pediatr 101:700–705CrossRefPubMed Waber LJ, Valle D, Neill C, DiMauro S, Shug A (1982) Carnitine deficiency presenting as familial cardiomyopathy: a treatable defect in carnitine transport. J Pediatr 101:700–705CrossRefPubMed
10.
go back to reference Masumura Y, Kobayashi A, Yamazaki N (1990) Myocardial free carnitine and fatty acylcarnitine levels in patients with chronic heart failure. Jpn Circ J 54:1471–1476CrossRefPubMed Masumura Y, Kobayashi A, Yamazaki N (1990) Myocardial free carnitine and fatty acylcarnitine levels in patients with chronic heart failure. Jpn Circ J 54:1471–1476CrossRefPubMed
11.
go back to reference Yamada S, Suzuki H, Kamioka M, Suzuki S, Kamiyama Y, Yoshihisa A, Saitoh S, Takeishi Y (2013) Sleep-disordered breathing increases risk for fatal ventricular arrhythmias in patients with chronic heart failure. Circ J 77:1466–1473CrossRefPubMed Yamada S, Suzuki H, Kamioka M, Suzuki S, Kamiyama Y, Yoshihisa A, Saitoh S, Takeishi Y (2013) Sleep-disordered breathing increases risk for fatal ventricular arrhythmias in patients with chronic heart failure. Circ J 77:1466–1473CrossRefPubMed
12.
go back to reference Nakagomi A, Seino Y, Endoh Y, Kusama Y, Atarashi H, Mizuno K (2010) Upregulation of monocyte proinflammatory cytokine production by C-reactive protein is significantly related to ongoing myocardial damage and future cardiac events in patients with chronic heart failure. J Card Fail 16:562–571CrossRefPubMed Nakagomi A, Seino Y, Endoh Y, Kusama Y, Atarashi H, Mizuno K (2010) Upregulation of monocyte proinflammatory cytokine production by C-reactive protein is significantly related to ongoing myocardial damage and future cardiac events in patients with chronic heart failure. J Card Fail 16:562–571CrossRefPubMed
13.
go back to reference Guven SF, Turkkani MH, Ciftci B, Ciftci TU, Erdogan Y (2012) The relationship between high-sensitivity C-reactive protein levels and the severity of obstructive sleep apnea. Sleep Breath 16:217–221CrossRefPubMed Guven SF, Turkkani MH, Ciftci B, Ciftci TU, Erdogan Y (2012) The relationship between high-sensitivity C-reactive protein levels and the severity of obstructive sleep apnea. Sleep Breath 16:217–221CrossRefPubMed
14.
go back to reference Randby A, Namtvedt SK, Einvik G, Hrubos-Strom H, Hagve TA, Somers VK, Omland T (2012) Obstructive sleep apnea is associated with increased high-sensitivity cardiac troponin T levels. Chest 142:639–646CrossRefPubMed Randby A, Namtvedt SK, Einvik G, Hrubos-Strom H, Hagve TA, Somers VK, Omland T (2012) Obstructive sleep apnea is associated with increased high-sensitivity cardiac troponin T levels. Chest 142:639–646CrossRefPubMed
15.
go back to reference Pekala J, Patkowska-Sokola B, Bodkowski R, Jamroz D, Nowakowski P, Lochynski S, Librowski T (2011) l-carnitine-metabolic functions and meaning in humans life. Curr Drug Metab 12:667–678CrossRefPubMed Pekala J, Patkowska-Sokola B, Bodkowski R, Jamroz D, Nowakowski P, Lochynski S, Librowski T (2011) l-carnitine-metabolic functions and meaning in humans life. Curr Drug Metab 12:667–678CrossRefPubMed
16.
go back to reference Omori Y, Ohtani T, Sakata Y, Mano T, Takeda Y, Tamaki S, Tsukamoto Y, Kamimura D, Aizawa Y, Miwa T, Komuro I, Soga T, Yamamoto K (2012) l-Carnitine prevents the development of ventricular fibrosis and heart failure with preserved ejection fraction in hypertensive heart disease. J Hypertens 30:1834–1844CrossRefPubMed Omori Y, Ohtani T, Sakata Y, Mano T, Takeda Y, Tamaki S, Tsukamoto Y, Kamimura D, Aizawa Y, Miwa T, Komuro I, Soga T, Yamamoto K (2012) l-Carnitine prevents the development of ventricular fibrosis and heart failure with preserved ejection fraction in hypertensive heart disease. J Hypertens 30:1834–1844CrossRefPubMed
17.
go back to reference Pauly DF, Pepine CJ (2003) The role of carnitine in myocardial dysfunction. Am J Kidney Dis 41:S35–S43CrossRefPubMed Pauly DF, Pepine CJ (2003) The role of carnitine in myocardial dysfunction. Am J Kidney Dis 41:S35–S43CrossRefPubMed
18.
go back to reference Serati AR, Motamedi MR, Emami S, Varedi P, Movahed MR (2010) l-carnitine treatment in patients with mild diastolic heart failure is associated with improvement in diastolic function and symptoms. Cardiology 116:178–182CrossRefPubMed Serati AR, Motamedi MR, Emami S, Varedi P, Movahed MR (2010) l-carnitine treatment in patients with mild diastolic heart failure is associated with improvement in diastolic function and symptoms. Cardiology 116:178–182CrossRefPubMed
19.
go back to reference Regitz V, Shug AL, Fleck E (1990) Defective myocardial carnitine metabolism in congestive heart failure secondary to dilated cardiomyopathy and to coronary, hypertensive and valvular heart diseases. Am J Cardiol 65:755–760CrossRefPubMed Regitz V, Shug AL, Fleck E (1990) Defective myocardial carnitine metabolism in congestive heart failure secondary to dilated cardiomyopathy and to coronary, hypertensive and valvular heart diseases. Am J Cardiol 65:755–760CrossRefPubMed
20.
go back to reference Matsui S, Sugita T, Matoba M, Murakami E, Takekoshi N, Shinka T, Matsumoto I (1994) Urinary carnitine excretion in patients with heart failure. Clin Cardiol 17:301–305CrossRefPubMed Matsui S, Sugita T, Matoba M, Murakami E, Takekoshi N, Shinka T, Matsumoto I (1994) Urinary carnitine excretion in patients with heart failure. Clin Cardiol 17:301–305CrossRefPubMed
21.
go back to reference Vescovo G, Ravara B, Gobbo V, Dalla Libera L (2005) Inflammation and perturbation of the l-carnitine system in heart failure. Eur J Heart Fail 7:997–1002CrossRefPubMed Vescovo G, Ravara B, Gobbo V, Dalla Libera L (2005) Inflammation and perturbation of the l-carnitine system in heart failure. Eur J Heart Fail 7:997–1002CrossRefPubMed
22.
go back to reference Moller DS, Lind P, Strunge B, Pedersen EB (2003) Abnormal vasoactive hormones and 24-hour blood pressure in obstructive sleep apnea. Am J Hypertens 16:274–280CrossRefPubMed Moller DS, Lind P, Strunge B, Pedersen EB (2003) Abnormal vasoactive hormones and 24-hour blood pressure in obstructive sleep apnea. Am J Hypertens 16:274–280CrossRefPubMed
23.
go back to reference Zoccali C, Mallamaci F, Tripepi G (2002) Nocturnal hypoxemia predicts incident cardiovascular complications in dialysis patients. J Am Soc Nephrol 13:729–733CrossRefPubMed Zoccali C, Mallamaci F, Tripepi G (2002) Nocturnal hypoxemia predicts incident cardiovascular complications in dialysis patients. J Am Soc Nephrol 13:729–733CrossRefPubMed
24.
go back to reference Foley RN, Parfrey PS, Sarnak MJ (1998) Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 9:S16–S23PubMed Foley RN, Parfrey PS, Sarnak MJ (1998) Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 9:S16–S23PubMed
25.
go back to reference Sklar AH, Chaudhary BA, Harp R (1989) Nocturnal urinary protein excretion rates in patients with sleep apnea. Nephron 51:35–38CrossRefPubMed Sklar AH, Chaudhary BA, Harp R (1989) Nocturnal urinary protein excretion rates in patients with sleep apnea. Nephron 51:35–38CrossRefPubMed
26.
go back to reference Kanbay A, Buyukoglan H, Ozdogan N, Kaya E, Oymak FS, Gulmez I, Demir R, Kokturk O, Covic A (2012) Obstructive sleep apnea syndrome is related to the progression of chronic kidney disease. Int Urol Nephrol 44:535–539CrossRefPubMed Kanbay A, Buyukoglan H, Ozdogan N, Kaya E, Oymak FS, Gulmez I, Demir R, Kokturk O, Covic A (2012) Obstructive sleep apnea syndrome is related to the progression of chronic kidney disease. Int Urol Nephrol 44:535–539CrossRefPubMed
27.
go back to reference Dursunoglu D, Dursunoglu N, Evrengul H, Ozkurt S, Kuru O, Kilic M, Fisekci F (2005) Impact of obstructive sleep apnoea on left ventricular mass and global function. Eur Respir J 26:283–288CrossRefPubMed Dursunoglu D, Dursunoglu N, Evrengul H, Ozkurt S, Kuru O, Kilic M, Fisekci F (2005) Impact of obstructive sleep apnoea on left ventricular mass and global function. Eur Respir J 26:283–288CrossRefPubMed
28.
go back to reference Grube M, Ameling S, Noutsias M, Kock K, Triebel I, Bonitz K, Meissner K, Jedlitschky G, Herda LR, Reinthaler M, Rohde M, Hoffmann W, Kuhl U, Schultheiss HP, Volker U, Felix SB, Klingel K, Kandolf R, Kroemer HK (2011) Selective regulation of cardiac organic cation transporter novel type 2 (OCTN2) in dilated cardiomyopathy. Am J Pathol 178:2547–2559CrossRefPubMedCentralPubMed Grube M, Ameling S, Noutsias M, Kock K, Triebel I, Bonitz K, Meissner K, Jedlitschky G, Herda LR, Reinthaler M, Rohde M, Hoffmann W, Kuhl U, Schultheiss HP, Volker U, Felix SB, Klingel K, Kandolf R, Kroemer HK (2011) Selective regulation of cardiac organic cation transporter novel type 2 (OCTN2) in dilated cardiomyopathy. Am J Pathol 178:2547–2559CrossRefPubMedCentralPubMed
29.
go back to reference Adams SH, Hoppel CL, Lok KH, Zhao L, Wong SW, Minkler PE, Hwang DH, Newman JW, Garvey WT (2009) Plasma acylcarnitine profiles suggest incomplete long-chain fatty acid beta-oxidation and altered tricarboxylic acid cycle activity in type 2 diabetic African–American women. J Nutr 139:1073–1081CrossRefPubMedCentralPubMed Adams SH, Hoppel CL, Lok KH, Zhao L, Wong SW, Minkler PE, Hwang DH, Newman JW, Garvey WT (2009) Plasma acylcarnitine profiles suggest incomplete long-chain fatty acid beta-oxidation and altered tricarboxylic acid cycle activity in type 2 diabetic African–American women. J Nutr 139:1073–1081CrossRefPubMedCentralPubMed
30.
go back to reference Mihalik SJ, Goodpaster BH, Kelley DE, Chace DH, Vockley J, Toledo FG, DeLany JP (2010) Increased levels of plasma acylcarnitines in obesity and type 2 diabetes and identification of a marker of glucolipotoxicity. Obesity (Silver Spring) 18:1695–1700CrossRef Mihalik SJ, Goodpaster BH, Kelley DE, Chace DH, Vockley J, Toledo FG, DeLany JP (2010) Increased levels of plasma acylcarnitines in obesity and type 2 diabetes and identification of a marker of glucolipotoxicity. Obesity (Silver Spring) 18:1695–1700CrossRef
31.
go back to reference Hannon TS, Lee S, Chakravorty S, Lin Y, Arslanian SA (2011) Sleep-disordered breathing in obese adolescents is associated with visceral adiposity and markers of insulin resistance. Int J Pediatr Obes 6:157–160CrossRefPubMedCentralPubMed Hannon TS, Lee S, Chakravorty S, Lin Y, Arslanian SA (2011) Sleep-disordered breathing in obese adolescents is associated with visceral adiposity and markers of insulin resistance. Int J Pediatr Obes 6:157–160CrossRefPubMedCentralPubMed
32.
go back to reference Flemons WW, Littner MR, Rowley JA, Gay P, Anderson WM, Hudgel DW, McEvoy RD, Loube DI (2003) Home diagnosis of sleep apnea: a systematic review of the literature. An evidence review cosponsored by the American Academy of Sleep Medicine, the American College of Chest Physicians, and the American Thoracic Society. Chest 124:1543–1579CrossRefPubMed Flemons WW, Littner MR, Rowley JA, Gay P, Anderson WM, Hudgel DW, McEvoy RD, Loube DI (2003) Home diagnosis of sleep apnea: a systematic review of the literature. An evidence review cosponsored by the American Academy of Sleep Medicine, the American College of Chest Physicians, and the American Thoracic Society. Chest 124:1543–1579CrossRefPubMed
Metadata
Title
Impact of sleep-disordered breathing on myocardial damage and metabolism in patients with chronic heart failure
Authors
Makiko Miyata
Akiomi Yoshihisa
Hiroyuki Yamauchi
Takashi Owada
Takamasa Sato
Satoshi Suzuki
Koichi Sugimoto
Takayoshi Yamaki
Hiroyuki Kunii
Kazuhiko Nakazato
Hitoshi Suzuki
Shu-ichi Saitoh
Yasuchika Takeishi
Publication date
01-05-2015
Publisher
Springer Japan
Published in
Heart and Vessels / Issue 3/2015
Print ISSN: 0910-8327
Electronic ISSN: 1615-2573
DOI
https://doi.org/10.1007/s00380-014-0479-6

Other articles of this Issue 3/2015

Heart and Vessels 3/2015 Go to the issue

Editorial

Editorial